Probably, given that most CHM were developed in a different medical theoretical system in China, the approved herbal drugs currently used in China will need further R&D before they can be safely used in the EU member states. For pharmaceutical companies in both China and EU Member States developing new herbal medicines, what industrial and legal criteria should be observed so that their products will be approvable in both Continents? WP7 will investigate if functional genomics may provide an additional and efficient component of the approval procedures of CHM for the EU …more